Trump received COVID-19 drugs developed from human fetal tissue
At least two drugs used to treat President Trump’s coronavirus infection have been tested in cells derived from fetal tissue, contradicting the Trump administration’s opposition to the use of human embryonic cell lines in medical research . The drugs are remdesivir, an antiviral and an experimental cocktail of monoclonal antibodies produced by Regeneron. A similar investigational drug produced by Eli Lilly has also been tested using cells derived from fetal tissue. Last year, the Trump administration cut federal funding for many projects using fetal tissue or embryonic stem cell lines, responding to a basic demand from anti-abortion activists.
President Trump said this week that he was “cured” of COVID-19 after receiving Regeneron antibody treatment. The drug is still in clinical trials and is not FDA approved. The Regeneron billionaire CEO was a member of President Trump’s Golf Resort in Westchester, New York, and met Trump in May. Following the meeting in July, Regeneron received $ 450 million in government funding for the Trump administration’s vaccination program known as “Operation Warp Speed.” Trump’s 2017 filing with the United States Office of Government Ethics shows that Trump was invested in both Regeneron and Gilead Sciences – the maker of remdesivir, which Trump also takes.